Clinical Trial Search

Primary: Clinical Efficacy of 2 Dose Regimens of Favipiravir Compared With Placebo in Treating Patients With Influenza — 100.4; 86.5; 91.9 hours — p=.05

Primary: Toxicity — 8; 2 participants

Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 48 — 90; 83 Percentage of…

Primary: Progression Free Survival (PFS) — 52; 56.5 estimated percentage of participants

Primary: Antipsychotic Efficacy — -2.73; -5.79; NA; -3.06 Score on the SAPS-PD scale

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at 8 Weeks — -26.6; -23.7; -27.0 units on a scale — p=0.05

Primary: Induction Phase: Pain Intensity Difference at 10 Minutes (PID10) After Treatment — 2.5; 1.4 units on a scale — p=0.002

Primary: Change From Baseline in MADRS Total Score at Week 8 — -16.53; -14.38 units on a scale — p=0.0018

Primary: Maximum Plasma Level (Cmax) of Dapsone — 11.7; 14.1; 13.0; 17.6 Nanograms/Milliliter (ng/mL)

Primary: Change in Overall Lifting and Tightening of Treated Tissue

Primary: Geometric Mean Human Serum Bactericidal Activity Titers Against N Meningitidis Serogroup C 28 Days After Vaccination — 2.1; 2.16; 2.15; 9.84 Titers — p=<0.05

Primary: Proportion of Subjects Achieving a Clinical Disease Activity Index (CDAI) Decrease of Greater Than or Equal to 10 Points in the Cimzia Treatment Group Compared to the…

Primary: Antipsychotic Efficacy — -5.9; -5.8; -6.7; NA Score on the SAPS H+D scale

Primary: G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period…

Primary: The Modified Rankin Scale Score — 3.9; 3.4; 4.0; 4.4 units on a scale